Vancouver, British Columbia — December 18, 2025 — Leads & Copy — InMed Pharmaceuticals Inc. (NASDAQ: INM) announced the results of its annual general and special meeting of shareholders, held on December 17, 2025.
Shareholders voted on matters outlined in the notice of meeting and management information circular dated November 3, 2025. Of the company’s 2,804,186 issued and outstanding common shares, 993,491 were represented in person or by proxy at the meeting, representing approximately 35.43%.
The election of the board of directors resulted in the following votes:
Eric A. Adams: 125,352 votes for (82.03%), 27,469 votes withheld (17.98%).
Andrew Hull: 125,315 votes for (82.00%), 27,506 votes withheld (18.00%).
Nicole Lemerond: 125,485 votes for (82.11%), 27,336 votes withheld (17.89%).
Neil Klompas: 125,444 votes for (82.09%), 27,377 votes withheld (17.91%).
John Bathery: 125,227 votes for (81.94%), 27,594 votes withheld (18.06%).
Shareholders also approved CBIZ CPAs P.C. as the company’s auditors for the coming year.
A vote also approved the potential issuance of 20% or more of the company’s common shares issued and outstanding as of December 13, 2024, under the Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., as amended on June 13, 2025, in accordance with Nasdaq Listing Rules 5635(d) and 5635(b).
InMed filed a report of voting results on SEDAR+ at www.sedarplus.ca on December 17, 2025.
InMed Pharmaceuticals is focused on developing small molecule drug candidates targeting CB1/CB2 receptors. The company’s pipeline includes programs for Alzheimer’s, ocular, and dermatological indications.
Investor Contact:
Colin Clancy
Vice President, Investor Relations and Corporate Communications
T: +1 604 416 0999
E: ir@inmedpharma.com
Source: InMed Pharmaceuticals Inc.
